TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Confirmed SARS-CoV-2 viral infection~* Advanced COVID-19 with score of 3 or 4 on NIAID scale (first 40 patients) or score of 3 on NIAID scale (last 40 patient~* Has at least one of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath, confusion or severe lower respiratory symptoms~* Off antiviral medications at least 24 hours prior to first dose of study drug (except for remdesivir)~* Able to provide consent~* Agree to appropriate methods of contraception~Exclusion Criteria:~* In critical condition or has ARDS~* On invasive mechanical ventilation or ECMO~* Bacterial or fungal infection~* Pregnant or lactating (women)~* ALT \>5x ULN, bilirubin \>2x ULN, INR outside of normal limits at screening~* eGFR \<30 mL/min~* Clinically relevant serious co-morbid medical conditions~* Treatment with any immunosuppressive therapy within 30 days prior to screening~* Treatment with another investigational drug within 30 days or 5 half-lives of drug prior to screening~* Prior treatment with the study drug (MMPD) or treatment with remdesivir more than 24 hours prior to the first randomized dose of study drug~* Known hypersensitivity to the inactive ingredients in the study drug (MMPD or placebo) or any ingredient of remdesivir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MMPD + remdesivir (Type: ACTIVE_COMPARATOR): Study subjects will receive MMPD oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
- Placebo + remdesivir (Type: PLACEBO_COMPARATOR): Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Marcaine Use in Laparoscopic Gynecological Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Ages 18-50~  * BMI 20-35~ * Gynecologic ambulatory cases only~ * Total of 3 incisions, with left and right incisions both being 5mm-10mm in size~ * Not taking pain medications prior to surgery~ * Length of surgery up to 3 hours~ * PACU stay up to 6 hours~ * Willing and able to sign informed consent~Exclusion Criteria:~* • Age or BMI out of range~  * Surgery longer than 3 hours or PACU stay longer than 6 hours~ * patients with chronic pelvic pain~ * Oncologic cases~ * Pregnant patients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Marcaine administered pre-incision. (Type: ACTIVE_COMPARATOR): Pre-operative administration, using both the specific drug - Marcaine 0.25%- and total amount - 5cc per incision.
- Marcaine administered post-incision (Type: ACTIVE_COMPARATOR): Marcaine 0.25% administered post-incision, total amount 5cc per incision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects, ages 18-45 years~* Experienced a major depressive episode in the postpartum period beginning within the first 4 weeks following delivery and with moderate or severe symptoms (\>12 EPDS or \>14 HAM-D).~* No or partial response to adequate doses of SSRI medications to treat PND for longer than 6 weeks.~* PND patients will be requested to maintain the stable dose of antidepressants while enrolled in the study trial.~* Patients that can speak and read the English language, are able to understand the study procedures and sign the informed consent~Exclusion Criteria:~* No current or past psychosis or severe personality disorder.~* No current substance abuse or dependence.~* No serious and imminent suicidal or homicidal risk.~* No recent or history of major and unstable medical problems that affect brain anatomy, neurochemistry, or function.~* Not diagnosed with cardiovascular disorders.~* No increased risk of laryngospasm or active upper respiratory infections.~* Not diagnosed with an intellectual disability or neurodegenerative diseases.~* Mothers that are currently breastfeeding.~* No current pregnancy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg (Type: EXPERIMENTAL): single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)
- Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg (Type: EXPERIMENTAL): single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SIXES: Should I eXtract Every Six? A Study of the Extraction of Permanent Molar Teeth in Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 7 -11 years~* Dental History: Able to co-operate with dental treatment~* Regular attender or considered likely to return for follow-up Social History~* Child and carer able to understand study documentation and give consent to participate in study~Dental condition:~* One or two lower FPMs requiring extraction~* Upper FPMs are sound or restorable/ restored with good long term prognosis (i.e. has or requires a single surface restoration with caries less than half-way into dentine, restoration with a simple restoration)~* Confirmed presence of all second premolars and all second molars~Exclusion Criteria~* Medical History: Medical contraindication to dental extractions~* Dental condition: Poor prognosis of premolars or permanent second molar teeth~* All four upper incisors in crossbite~* Poor prognosis of upper FPM~* Confirmed absence of one or more second premolars and second molars~* Declines to have impressions taken

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Compensatory Extraction (Type: ACTIVE_COMPARATOR): Patients allocated to this group, both the upper FPM and lower FPM teeth will be extracted.
- No Compensatory Extraction (Type: ACTIVE_COMPARATOR): Patients allocated to this group, only the lower FPM tooth will be extracted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Quetiapine in Generalised Social Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written Confirmed Consent,~* All patients meet the DSM IV criteria for generalized social anxiety disorder,~* A score ≥ 60 on the LSAS,~* male and female aged between 18 and 65 years~Exclusion Criteria:~* Presence of any primary axis I diagnosis other than social anxiety disorder according to DSM-IV,~* alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months,~* any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder,~* patients at risk of suicide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Estrogens Effect on Pain in Postmenopausal Women Suffering of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 49-60 years~* Body mass index (BMI) of \< 30~* Met the ACR-90 criteria for the diagnosis of fibromyalgia~* Postmenopausal state since at least six months~* Not been using any hormonal treatments for the past three months~* Had normal mammography screenings~Exclusion Criteria:~* Using psychotropic drugs or having a history of thromboembolism~* Diabetes mellitus, polyneuropathy, chronic liver disease,~* Alcohol or substance abuse, hemoglobinopathy,~* Endometrial adenomatous hyperplasia, or malignancy.~* Presence of untreated hypertension (\>160/95).~* Undiagnosed vaginal bleedings

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with transdermal 17β-estradiol (Type: EXPERIMENTAL): None
- Control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of generalized anxiety disorder (GAD)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- active antidepressant drug comparator (Type: ACTIVE_COMPARATOR): Venlafaxine ER
- Sugar pill (Type: PLACEBO_COMPARATOR): Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
- Herbal treatment kava (Type: EXPERIMENTAL): Kava

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Study of an Exercise Program for Youth With Persistent Symptoms After Concussion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of concussion~* have at least one post-concussion symptom (as measured by the Post Concussion Symptom Inventory)~* are at least 4 weeks post injury~* between the ages of 10 and 18 years~* ability to speak English~* ability to demonstrate capacity to consent to study~Exclusion Criteria:~* prior moderate or severe brain injury~* neck pain/dysfunction or oculormotor/vestibular dysfunction, developmental delays, mental health disorders or chronic pain conditions that prevent participation in active rehabilitation, assessment of gait and balance, or participation in cognitive testing~* participating in any other physical rehabilitation interventions for post-concussion symptoms (e.g., physiotherapy, massage therapy, chiropractic) at time of enrollment and throughout the duration of the study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Active Rehabilitation (Type: EXPERIMENTAL): Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
- Comprehensive Education Intervention (Type: ACTIVE_COMPARATOR): Comprehensive Education Intervention (Standard Care) only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Obesity Hypoventilation Syndrome Prevalence Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 21 yrs. of age~* Referred to sleep lab for diagnostic PSG, initial titration PSG or split night PSG as routine clinical care~* BMI greater than or equal to 30kg/m2~Exclusion Criteria:~* Acutely ill or medically unstable to participate per PI~* Current positive airway pressure(PAP therapy)users~* Medical History of Chronic Obstructive Pulmonary Disease(COPD)~* Incapable of providing own informed consent~* BMI less than 30kg/m2

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMI greater than or equal to 30kg/m2 -venous (Type: None): BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
- BMI greater than or equal to 30kg/m2 - arterial (Type: None): BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed colorectal adenocarcinoma meeting the following criteria:~  * Exclusively peritoneal carcinomatosis (no other metastases)~ * Resectable disease~* Primary tumor may be same in the same location as another synchronous carcinomatosis~* Patients with metastatic disease who have been in complete remission for more than 1 year are eligible regardless of prior chemotherapy~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Life expectancy ≥ 12 weeks~* ANC ≥ 1.5 x 10\^9/L~* Platelet count ≥ 100 x 10\^9/L~* Hemoglobin ≥ 10 g/dL~* Bilirubin ≤ 1.25 times upper limit of normal (ULN)~* AST and ALT ≤ 3 times ULN~* Creatinine ≤ 1.25 times ULN~* Creatinine clearance ≥ 30 mL/min~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No allergy, hypersensitivity, or other contraindication to leucovorin calcium, oxaliplatin, or fluorouracil~* No other noncancerous disease that would preclude study therapy~* Good nutritional status~* No sensitive peripheral neuropathy with functional impairment~* No hypoplasia or bone marrow failure~* No clinically significant cardiovascular disease within the past year (e.g., unstable angina or myocardial infarction)~* No other cancer within the past 5 years unless in complete remission with the exception of cervical carcinoma in situ or basal cell cancer~* No patients deprived of liberty or under supervision~* No psychological, social, familial, or geographical reasons prohibiting follow-up~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 1 year since prior adjuvant chemotherapy, including prior therapy with oxaliplatin and/or cetuximab~* No prophylactic phenytoin (Dihydan®, Dilantin®)~* No prior yellow fever vaccine~* More than 1 month since participation in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy + Cetuximab (Type: EXPERIMENTAL): Surgery + Chemotherapy + Cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet diagnosis of mild Alzheimer's disease~* Must have a family member or caregiver who is willing to attend all study visits and provide information on your participation in the study~* If female, must be post-menopausal~* Must be able to swallow tablets~Exclusion Criteria:~* Metal implants or medical devises unsafe for MRI use~* Pre-menopausal female~* HIstory of recent head injury~* Significant major, life-threatening illness or injury (e.g., stroke, AIDS, etc.)~* Vascular dementia or any dementia other than Alzheimer's Disease~* History of significant alcoholism or drug abuse~* History of seizure disorder, developmental delay or major psychiatric illness

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Razadyne ER (Type: EXPERIMENTAL): galantamine treatment group
- Aricept (Type: EXPERIMENTAL): Aricept Treatment Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Paroxysmal and Persistent Atrial Fibrillation refractory eligible for AF ablation as per HRS/ECAS/EHRA consensus statement.\[23\] Paroxysmal AF is defined as two or more episodes of AF lasting less than 7 days in duration during the last 6 months before enrollment. Persistent AF is defined as AF lasting more than 7 days or requiring cardioversion for termination.~2. Hypertension (\>140/80 mm Hg) on treatment with at least 1 hypertensive medication.~3. GFR \>60ml/dl using Cockcroft- Gault equation~Exclusion Criteria:~1. Secondary causes of hypertension~2. Severe renal artery stenosis or dual renal arteries~3. Congestive heart failure with NYHA class III or IV status~4. EF\< 35%~5. LA Diameter \>6 cm~6. Previous AF ablation~7. Previous renal artery stent or angioplasty~8. Severe contrast allergy~9. Inability to give informed consent~10. Solitary kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AF Ablation alone (Type: ACTIVE_COMPARATOR): Clinical AF ablation performed as deemed appropriate by operator
- AF ablation with Renal Denervation (Type: EXPERIMENTAL): Renal denervation performed using the same ablation catheter after clinical AF ablation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Peripheral Oxygen Saturation (SpO2) Directed Oxygen Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18 years or older and admitted into ICU, with expected stay in ICU more than 72 hours or longer.~Exclusion Criteria:~* under 18 years old, expected stay in ICU less than 72 hours, unconsented inclusion, ICU readmission, patients with acute exacerbation of chronic obstruction disease, patients with severe acute respiratory distress syndrome (defined as PaO2/FiO2 ≤ 100mmHg and PEEP ≥10cmH2O), decision to withhold life-sustaining treatment, physician forgetting to screen during 12 hours after admission, pregnancy, patients with acute myocardial infarction, paraquat poisoning and patients on extracorporeal membrane oxygenation (ECMO) or planned to be on ECMO.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low SpO2 group (Type: EXPERIMENTAL): SpO2 90-95%, with FiO2 as low as possible.
- High SpO2 group (Type: ACTIVE_COMPARATOR): SpO2 96-100%, with FiO2 no lower than 30%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues